Psilocybin for Smoking Cessation
3 proposed mechanisms
Qualitative interviews with psilocybin-treated smokers identified three distinct pathways: identity shift, heightened body awareness, and motivation that felt externally imposed — together explaining why this treatment works differently from NRT or varenicline.
Noorani et al., Journal of Psychoactive Drugs, 2018
Identity shift
participants stopped identifying as 'a smoker'
MEQ scores
mystical experience depth predicted quit success
15 participants
qualitative interviews with entire Johnson pilot cohort
Noorani et al., Journal of Psychoactive Drugs, 2018
View as image ↗The clinical outcomes of psilocybin for smoking cessation are striking enough that they have drawn serious scientific attention. But the outcomes data raises a question that the outcomes data alone cannot answer: why does it work? Nicotine replacement therapy delivers more nicotine. Varenicline blocks nicotine receptors. Bupropion addresses dopamine pathways. All of these treatments operate on the chemistry of the addiction directly. Psilocybin operates on something different, and understanding the proposed psilocybin nicotine addiction mechanisms requires looking at what smokers themselves say changed during treatment, not just what the quit rates measured.
Two studies provide the core mechanism evidence. Johnson et al.'s 2014 companion paper found that mystical experience scores during psilocybin sessions predicted who quit and who didn't.[1] Noorani et al.'s 2018 qualitative study interviewed every participant from the Johnson pilot and identified three recurring themes that explained how, from the participants' perspective, the treatment produced lasting behavior change.[2] Neither study proves mechanism in the strict experimental sense. But together they provide the best current picture of what psilocybin actually does to the grip that nicotine has on a person's identity, cognition, and sense of self.
The clinical evidence base for psilocybin in addiction, including its results in alcohol use disorder and other substances, is reviewed in the psilocybin and addiction overview. This article focuses specifically on why psilocybin is proposed to break nicotine's hold.
Key Takeaways
- In a qualitative study of 15 smokers treated with psilocybin, Noorani et al. (2018) identified three recurring mechanisms participants described: identity shift, heightened body awareness, and motivation that felt externally imposed rather than self-generated
- Johnson et al. (2014) found that mystical experience scores (MEQ) during psilocybin sessions predicted smoking cessation outcomes: greater session depth correlated with better quit rates
- Participants who rated their psilocybin session among the most meaningful experiences of their lives had higher quit rates (Johnson et al., 2014)
- Standard treatments (NRT, varenicline) suppress cravings chemically but do not address the identity or habit-pattern dimensions of smoking — psilocybin appears to act on all three levels simultaneously
- A 2023 systematic review confirmed that psilocybin's mechanism of sustained behavior change via perspective shift appears consistent across addiction types, not specific to nicotine (Uprety et al., 2023)
- The mechanism evidence is correlational and qualitative — the causal chain from psilocybin session to nicotine abstinence is proposed but not yet established through controlled neuroimaging or mechanistic studies
Why Nicotine Addiction Is So Hard to Break — and What Standard Treatments Miss
Nicotine addiction is not primarily a problem of chemistry. It is a problem of chemistry woven into daily behavior patterns, social context, and identity.
The neurochemical layer is well understood. Nicotine binds to acetylcholine receptors and triggers dopamine release, producing reward and reinforcing the behavior. Over time, the reward system recalibrates around nicotine as a baseline, so its absence produces withdrawal rather than just the absence of pleasure.
But nicotine is unusual among addictive substances in how deeply it integrates with behavioral routines. Smokers don't just crave nicotine in a general sense. They have specific triggers: the cigarette after coffee, after a meal, during a work break, under stress. Each of these represents a learned behavioral association, a habit loop that runs almost automatically outside of conscious deliberation.
The deepest layer is identity. Many long-term smokers do not think of themselves as people who choose to smoke. They think of themselves as smokers. This is not a semantic distinction. When "smoking" is part of how someone defines themselves, quitting is not just breaking a habit, it is changing who they are. Standard treatments largely ignore this dimension.
Nicotine replacement therapy manages the withdrawal layer by supplying nicotine without the behavioral reinforcement of smoking. Varenicline, the most effective standard treatment, partially blocks nicotine receptors and reduces the reward signal. Both approaches require sustained daily adherence over weeks and months, and the majority of people who quit with these tools eventually relapse, often because the identity and habit-loop dimensions of the addiction remain intact.
Psilocybin is being studied as a treatment that may work at a different level entirely. It does not deliver nicotine, block receptors, or require daily adherence. The proposed mechanism is not pharmacological in the conventional sense. It is psychological, experiential, and possibly neurological in ways that are still being mapped.
Three Proposed Mechanisms: What Qualitative Interviews with Psilocybin-Treated Smokers Revealed
The three proposed mechanisms for psilocybin's effectiveness in smoking cessation are: (1) identity shift, in which participants no longer identify as "a smoker" after the psilocybin experience (Noorani et al., 2018); (2) heightened body awareness, in which participants reported clearer perception of what smoking was doing to their physical health; and (3) externally imposed motivation, in which the drive to quit felt not like a personal decision but like something that had been placed in them by the experience itself.
These themes emerged from a qualitative analysis by Noorani and colleagues, who conducted in-depth interviews with the 15 participants who had received psilocybin-assisted therapy in the Johns Hopkins pilot study.[2] Qualitative methods were appropriate here because the mechanism of action was not yet understood, and quantitative outcome measures (quit rates, cotinine levels) could not explain why the treatment worked — only that it did.
The researchers coded participant accounts into themes and found that these three patterns appeared consistently across interviews, regardless of whether participants had quit successfully or relapsed. This consistency across outcomes makes the themes more credible as descriptions of what the treatment actually does, rather than post-hoc rationalizations by people who quit.
It is important to note what these three mechanisms are not: they are not direct reports of brain activity, receptor binding, or neural circuit changes. They are first-person accounts of psychological shifts. Whether these psychological shifts have specific neurological underpinnings that could be targeted or measured is an open question.
Mechanism One: Becoming Someone Who Doesn't Smoke
The most striking theme in Noorani's qualitative data was identity shift. Participants consistently reported that after their psilocybin session, they no longer felt like a smoker.[2] This was not described as a decision or a commitment made during the session. It was described as a change that had already happened, a fundamental shift in self-perception that smoking no longer felt consistent with.
For context: the participants in this cohort had been smoking for an average of 31 years and had made an average of 6 prior quit attempts. For most of them, smoking had been part of their identity for the majority of their adult lives. The idea that two psilocybin sessions embedded in a 15-week program could produce a lasting shift in self-concept is not pharmacologically trivial. No existing smoking cessation medication produces this kind of report.
The mechanism behind identity shift is hypothetical. One proposed explanation draws on psilocybin's known effects on the default mode network, the set of brain regions associated with self-referential thought and narrative identity. Psilocybin suppresses the default mode network during the acute experience, temporarily loosening the fixed patterns of self-concept that form part of what depression researchers call "rigid priors." Under this loosening, people may have greater access to alternative self-narratives, and the therapeutic context of the treatment, which explicitly frames the session as a step toward becoming a non-smoker, may shape which new identity sticks.
This is a hypothesis, not a proven mechanism. But it aligns with what participants reported.
Mechanism Two: Seeing Your Own Body Differently
The second theme from Noorani 2018 was heightened awareness of the body and its connection to health.[2] Participants described an enhanced clarity about what smoking was doing to them physically, not as new information they had learned but as a felt sense of the body that the psilocybin experience had opened up.
This is distinct from the fear-based approach of public health campaigns, which present smoking's health risks as threats to be avoided. The shift described by participants in Noorani's analysis was not fear or avoidance. It was described more as clarity or presence, an ability to perceive their physical experience without the habitual filtering that had normalized the costs of smoking.
Psychedelic experiences are often associated with heightened body awareness and a loosening of the habitual filters through which sensory experience is processed. Under psilocybin, the normal tendency to interpret physical sensations through prior expectations, what the brain has "decided" these sensations mean, can temporarily ease. This may produce a kind of unmediated physical experience that is more available to new meaning-making than ordinary consciousness.
Whether this heightened body awareness persists beyond the acute session, and whether it translates into maintained behavior change, was not possible to confirm from a qualitative study. But as a description of what participants experienced in the context of a treatment that produced durable behavior change, it is a meaningful data point.
Mechanism Three: Motivation That Didn't Feel Like a Personal Choice
The third theme was perhaps the most unusual from a clinical perspective. Participants in Noorani's study described the motivation to quit that emerged from their psilocybin session as feeling externally imposed rather than internally generated.[2]
In behavioral therapy frameworks, sustained change is typically understood as requiring intrinsic motivation, the person's own values and desires driving the behavior change. The expectation is that people change when they want to change. This is why many smoking cessation counselors focus on identifying the person's "reasons to quit" and building on those intrinsic motivators.
The participants in Noorani's study described something different. Rather than feeling that they had finally committed to quitting, they described the motivation as something that had happened to them during the session and remained with them afterward. The decision to quit did not feel like their decision. It felt like something that had been placed in them by the experience.
This is a strange phenomenon to describe in clinical terms. But it may be consistent with what psychological theorists have called "noetic quality," one of the defining features of mystical experiences, the sense of having been given insight rather than having worked it out. If the psilocybin experience operates in part by bypassing the deliberative cognition that maintains existing habits and identities, the resulting motivation might feel less like a choice and more like an event.
The clinical significance of this is not yet clear. But if motivation arising from an altered state of consciousness is more durable than motivation generated by ordinary deliberation, that could help explain the long-term quit rates seen in the follow-up data.
The Mystical Experience Predicts Who Quits: Session Depth Forecasts Success
The mechanism data from Noorani 2018 is qualitative. The data from Johnson et al.'s 2014 companion paper provides a quantitative complement, measuring something about the psilocybin session itself and testing whether it predicts outcomes.
Using the Mystical Experience Questionnaire, a standardized instrument measuring the depth and character of a psychedelic experience, Johnson and colleagues found that higher scores during the psilocybin session predicted better smoking cessation outcomes at follow-up.[1] Participants who rated their session among the most personally meaningful and significant experiences of their lives had higher rates of confirmed abstinence.
This finding is mechanistically important because it establishes that the therapeutic outcome is not independent of the quality of the psychedelic experience. If psilocybin worked purely by chemical effects on nicotine receptor systems, one would not expect the subjective depth of the experience to predict outcomes. The fact that it does suggests that the psychological experience, specifically the kind of profound subjective shift associated with high mystical experience scores, is part of the mechanism, not noise around the pharmacological signal.
This creates a significant difference between psilocybin and conventional pharmacotherapy. Varenicline works through a specific receptor mechanism that is largely independent of the patient's subjective response to the treatment. Psilocybin's mechanism, to the extent it is understood, appears to involve the subjective experience itself as an active ingredient.
The practical implication is that dose and context matter in ways they do not for typical medications. A low-dose session that does not produce significant mystical experience qualities may not deliver the same therapeutic effect as a high-dose session that does. This is consistent with the Johnson pilot protocol, which used relatively high weight-adjusted doses (30 mg/70 kg) in a carefully prepared therapeutic context.
For more on the mystical experience's role in addiction recovery specifically, see the mystical experience and addiction recovery. For the neuroscience underlying these changes, including what the default mode network disruption during psilocybin sessions does to habit circuitry, see how psilocybin breaks addiction: the neuroscience explained.
The Same Pattern Appears Across Multiple Addictions — and Why That's Significant
If psilocybin's mechanism in nicotine addiction were specific to nicotine pharmacology, one would expect the treatment to be less effective, or effective in different ways, in addictions involving different substances. The cross-addiction data suggests otherwise.
Uprety and colleagues' 2023 systematic review of psilocybin across addiction types, including alcohol use disorder and tobacco, found consistent evidence of a similar mechanism at work: sustained behavior change via psychedelic-induced perspective shifts.[3] The tobacco data showed the strongest abstinence outcomes, but the qualitative character of the treatment's mechanism, identity shift, heightened clarity, and the motivation produced by the psychedelic experience, appeared similar across substances.
This cross-substance pattern is evidence against a nicotine-specific pharmacological mechanism and evidence for a general psychological mechanism. Psilocybin does not appear to work in tobacco addiction because it does something specific to nicotine receptor systems. It appears to work because it produces a category of psychological experience, profound, meaningful, perspective-shifting, that enables sustained behavior change across a range of addiction types.
If this is correct, the mechanism is primarily experiential and psychological, and the neurobiological changes that underlie it, DMN disruption, increased neuroplasticity, loosened predictive priors, are the biology of that experience rather than a direct pharmacological intervention on addiction circuitry. This is a different model than almost any other addiction treatment.
For a broader view of nicotine craving and how psilocybin is proposed to reduce it, see psilocybin and craving reduction: mechanisms of action. For the clinical outcomes and how they compare to standard treatments, see psilocybin for smoking cessation: the Johns Hopkins results and the Johns Hopkins 80% quit rate study explained.
What the Evidence Can't Confirm Yet
The mechanism picture described in this article is more promising than most consumer reporting suggests, and more uncertain than most science reporting suggests.
The Noorani 2018 study is qualitative. Its three themes, identity shift, body awareness, and externally imposed motivation, represent what participants reported. They do not represent independently verified descriptions of what happened neurologically. Two participants could describe the same subjective experience for different underlying reasons, and the relationship between the psychological reports and the neural events is not yet established.
The Johnson 2014 MEQ finding is correlational. Mystical experience scores predicted quit success in the same cohort, but correlation does not establish that the mystical experience caused the quit success. It is possible that participants who were more likely to quit for other reasons (higher motivation, more positive expectancy, different baseline psychology) also happened to have deeper psilocybin experiences for the same underlying reasons.
Neither study includes neuroimaging data on nicotine craving circuits before and after treatment. The proposed mechanism involving default mode network disruption, habit loop interruption, and identity restructuring is consistent with the data and with broader psilocybin neuroscience, but it has not been directly measured in the context of nicotine addiction.
What the evidence does establish: the qualitative reports from treated smokers are internally coherent and consistent across individuals. The MEQ correlation with outcomes suggests the depth of the experience is therapeutically relevant. The cross-addiction pattern suggests the mechanism is not nicotine-specific. And the treatment effects are durable in a way that standard pharmacotherapy rarely achieves. The mechanism is being worked out, but the effects that need explaining are real.
The Bottom Line
Two studies provide the primary mechanism evidence for psilocybin in nicotine addiction. Noorani et al. (2018) found that treated smokers consistently described three psychological shifts: identity transformation, heightened body awareness, and motivation that felt externally given rather than chosen. Johnson et al. (2014) found that the depth of the psilocybin experience, measured by mystical experience scores, predicted who quit. Together these suggest psilocybin works at the levels of identity and subjective experience rather than through direct pharmacological action on nicotine pathways. The mechanism remains proposed, not proven, and larger controlled studies with neuroimaging endpoints will be needed to confirm the causal chain.
Frequently Asked Questions
Sources & References
- 1. Source details for this reference are not yet available.
- 2. Source details for this reference are not yet available.
- 3. Source details for this reference are not yet available.